Cost-effectiveness of cetuximab in combination with irinotecan compared with current care in metastatic colorectal cancer after failure on irinotecan - A Belgian analysis

Acta Clinica Belgica

Volumn 62, Issue 6, 2007, Pages 419-425

  Annemans, Lieven ^a   Van Cutsem, E ^b   Humblet, Y ^c   Van Laethem, J L ^d   Bleiberg, H ^e  

^a GHENT UNIVERSITY   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^d ERASME HOSPITAL   (Belgium)

^e JULES BORDET INSTITUTE   (Belgium)

Author keywords

Belgium; Cetuximab; Colorectal cancer; Cost effectiveness; Metastatic

Indexed keywords

CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; RALTITREXED;

ARTICLE; BELGIUM; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HEALTH CARE COST; HUMAN; METASTASIS;

EID: 39049148881     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1179/acb.2007.061     Document Type: Article

References (12)

1. Belgisch Werk tegen Kanker. http://www.kankerregister.org.
2. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-7.
3. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22: 1209-14.
4. Köhne CH, van Cutsem E, Wils J, et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005; 23: 4856-65.
5. Rothenberg ML, Oza AM, Burger B, et al. Final results of a phase III trial of 5-FU/leucovorin versus oxaliplatin versus the combination in patients with metastatic colorectal cancer following irinotecan, 5-FU, and leucovorin. Proc Am Soc Clin Oncol 2003; 22: Abstract 2003. Virtual presentation at www.asco.org.
6. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-14.
7. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45.
8. Folprecht G, Lutz MP, Schoffski P, et al. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 2006; 17: 450-6.
9. Saltz LB, Meropol NJ, Loehrer PJ, Sr., Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-8.
10. De Jong KP, Stellema R, Karrenbeld A, et al. Clinical relevance of transforming growth factor alpha, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors. Hepatology 1998; 28: 971-9.
11. Mayer A, Takimoto M, Fritz E, Schellander G, Kofler K, Ludwig H. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 1993; 71: 2454-60.
12. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995; 1: 1311-8.